Badgley Phelps Wealth Managers
VRTX icon

Badgley Phelps Wealth Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

Badgley Phelps Wealth Managers’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.26M Buy
13,893
+11,963
+620% +$6.13M 0.13% 120
2026
Q2 		$959K Buy
1,930
+49
+3% +$21.7K 0.02% 204
2026
Q1 		$840K Sell
1,881
-6
-0.3% -$2.8K 0.02% 211
2025
Q4 		$855K Hold
1,887
– – 0.02% 206
2025
Q3 		$739K Hold
1,887
– – 0.02% 201
2025
Q2 		$840K Buy
1,887
+22
+1% +$10.1K 0.02% 187
2025
Q1 		$904K Sell
1,865
-2
-0.1% -$932 0.02% 179
2024
Q4 		$752K Sell
1,867
-1
-0.1% -$464 0.02% 191
2024
Q3 		$869K Sell
1,868
-84
-4% -$40.4K 0.02% 179
2024
Q2 		$915K Buy
1,952
+100
+5% +$43.4K 0.02% 169
2024
Q1 		$774K Sell
1,852
-2
-0.1% -$845 0.02% 176
2023
Q4 		$754K Buy
+1,854
New +$685K 0.02% 172

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Badgley Phelps Wealth Managers's VRTX Position: Q3 2026 in Review

Badgley Phelps Wealth Managers increased its Vertex Pharmaceuticals (VRTX) stake by 620% in Q3 2026, buying an estimated $6.13M and bringing the position to 13,893 shares worth $7.26M. The position accounts for 0.13% of the portfolio, ranked #120.

Badgley Phelps Wealth Managers first reported a position in VRTX in Q4 2023 and has held it in 12 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Badgley Phelps Wealth Managers held 13,893 shares of Vertex Pharmaceuticals worth $7.26M as of Q3 2026.
  • Badgley Phelps Wealth Managers bought 11,963 Vertex Pharmaceuticals shares in Q3 2026, an estimated $6.13M.
  • Vertex Pharmaceuticals made up 0.13% of Badgley Phelps Wealth Managers's portfolio in Q3 2026, its #120 holding.
  • Badgley Phelps Wealth Managers first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Badgley Phelps Wealth Managers's 13F filing for Q3 2026, filed 22 Oct 2026.